ELAN Stock Forecast & Price Target

Elanco Animal Health is supported by a strong 2Q beat and raise, with total revenue of $1,368M, adjusted EBITDA of $288M, and adjusted diluted EPS of $0.34 all above consensus, while FY26 guidance was lifted for revenue, EBITDA, and EPS. The outlook is further strengthened by momentum in Zenrelia, Quattro, and Befrena, as management reported rising confidence in its Next Wave innovation portfolio and highlighted seven potential blockbuster launches that could drive sales growth, margin expansion, and deleveraging. The company’s diversified global footprint across pet health and farm animal markets, plus resilient demand in a $40B+ animal health industry, provides a durable base for continued top-line growth and improved profitability.

Elanco Animal Health is facing a fundamentally challenged outlook because the animal health industry is highly competitive, with rivals investing heavily in R&D while generic products, disruptive innovation, and potential competitor launches could pressure pricing and market share. Its pipeline and acquisition strategy may not produce commercially successful products, and regulatory restrictions on antibiotics and productivity products, along with disease outbreaks, customer consolidation, manufacturing issues, and weather-related disruptions, could weaken demand and create cost volatility. Even key growth drivers such as Zenrelia face adoption uncertainty, with KOLs expecting a challenging washout period and only gradual U.S. dose growth to 26.8 million, suggesting sales and EPS growth may fall below expectations.